MSV-allo / Citospin, Red de Terapia Celular - LARVOL DELTA

MSV_LE: Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Red de Terapia Celular | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

MSV_LE: Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Red de Terapia Celular | Not yet recruiting ➔ Recruiting

Enrollment open • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

MSV_LE: Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Red de Terapia Celular | N=36 ➔ 20 | Trial completion date: Jun 2024 ➔ Jul 2025 | Trial primary completion date: Dec 2023 ➔ Jul 2024

Enrollment change • Trial completion date • Trial primary completion date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) (clinicaltrials.gov) - P2 | N=24 | Completed | Sponsor: Red de Terapia Celular | Recruiting ➔ Completed

Trial completion • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

LUPUS NEPHRITIS TREATMENT WITH MESENCHYMAL CELLS (MSV-allo®). TRATAMIENTO DE LA NEFRITIS LÚPICA con células mesenquimales (MSV-allo®). (clinicaltrialsregister.eu) - P2 | N=20 | Ongoing | Sponsor: Hospital Universitario Rio Hortega

New P2 trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) (clinicaltrials.gov) - P2; N=24; Recruiting; Sponsor: Red de Terapia Celular; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Nov 2020 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) (clinicaltrials.gov) - P2; N=24; Recruiting; Sponsor: Red de Terapia Celular; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) (clinicaltrials.gov) - P2; N=24; Not yet recruiting; Sponsor: Red de Terapia Celular

Clinical • New P2 trial

Treatment of COVID-19 with allogeneic mesenchymal cells (MSV®). Tratamiento de COVID-19 con células mesenquimales alogénicas MSV® (clinicaltrialsregister.eu) - P2; N=24; Ongoing; Sponsor: CITOSPIN S.L.

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases